高级别浆液性卵巢癌的内分泌治疗:疗效量化与应答预测因素识别
本研究在爱丁堡癌症中心纳入269例复发高级别浆液性卵巢癌患者,评估内分泌治疗的疗效及预测因素。结果显示CA125应答率8.1%、临床获益率40.1%,雌激素受体组织评分>200和治疗间隔≥180天为独立预测因素。作者认为内分泌治疗可考虑作为推迟后续化疗的策略。
要点
- CA125应答率8.1%,临床获益率(应答或疾病稳定)40.1%。
- 雌激素受体组织评分>200(P=0.0016)为独立预测因素。
- 治疗间隔≥180天(P<0.0001)为独立预测因素。
核心结论
- 内分泌治疗可考虑作为复发高级别浆液性卵巢癌推迟后续化疗的可行策略。
- 雌激素受体组织评分>200且治疗间隔≥180天的患者最可能获益。
研究设计与样本
- 在爱丁堡癌症中心识别接受至少4周内分泌治疗用于一线化疗后复发疾病的高级别浆液性卵巢癌患者。
- 排除将内分泌治疗用作维持治疗或治疗持续时间未知者,共269例符合条件。
主要发现
- 269例中77.0%使用来曲唑,18.6%使用他莫昔芬,2.2%使用甲地孕酮,2.2%使用其他。
- 中位治疗持续时间为126天(范围28-1427天),32.7%持续≥180天,14.1%持续≥365天。
- CA125应答率和临床获益率(应答或疾病稳定)分别为8.1%和40.1%。
- 多变量分析显示雌激素受体组织评分>200(P=0.0016)和治疗间隔≥180天(P<0.0001)为独立预测因素。
关键数值与推荐
- CA125应答按改良GCIG标准评估。
- 评估的预测因素包括雌激素受体组织评分、治疗间隔、既往化疗线数和内分泌治疗类型。
临床怎么用
- 作者认为内分泌治疗可考虑作为复发高级别浆液性卵巢癌推迟后续化疗的可行策略。
- 作者认为雌激素受体组织评分>200且治疗间隔≥180天的患者最可能从内分泌治疗中获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The role of endocrine therapy (ET) in high grade serous ovarian carcinoma (HGSOC) is poorly defined due to the lack of phase III data and significant heterogeneity of clinical trials performed. In this study, we sought to identify predictive factors of endocrine sensitivity in HGSOC. METHODS: HGSOC patients who received at least four weeks of ET for relapsed disease following one line of chemotherapy at the Edinburgh Cancer Centre were identified. Exclusion criteria were use of endocrine therapy as maintenance therapy or of unknown duration. Duration of therapy and best CA125 response as per modified GCIG criteria were recorded. Oestrogen receptor (ER) histoscore, treatment free interval, prior lines of chemotherapy, and type of ET were evaluated as predictive factors. RESULTS: Of 431 patients identified, 269 were eligible (77.0% letrozole, 18.6% tamoxifen, 2.2% megesterol acetate, 2.2% other). The median duration of therapy was 126 days (range 28-1427 days). 32.7% remained on ET for ≥180 days and 14.1% for ≥365 days. The CA125 response and clinical benefit rates (response or stable disease) were 8.1% and 40.1% respectively. ER histoscore >200 (P = 0.0016) and a treatment free interval of ≥180 days (P < 0.0001) were independent predictive factors upon multivariable analysis. CONCLUSIONS: ET should be considered as a viable strategy to defer subsequent chemotherapy for relapsed HGSOC. Patients with an ER histoscore >200 and a treatment free interval of ≥180 days are most likely to derive benefit.
引用
- Stanley B, Hollis RL, Nunes H, et al. Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors. Gynecol Oncol. 2018. PMID: 30501904. doi:10.1016/j.ygyno.2018.11.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。